Acumen Pharmaceuticals (ABOS) Free Cash Flow (2020 - 2026)
Acumen Pharmaceuticals recorded quarterly Free Cash Flow of -$24.1 million in Q1 2026, down 26.35% quarter-over-quarter from -$19.1 million in Q4 2025, and up 29.45% year-over-year from -$18.6 million in Q1 2025.
Acumen Pharmaceuticals' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$24.1 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 29.45% year-over-year to -$24.1 million; the TTM figure through Mar 2026 stood at -$105.6 million (down 2.99% YoY), while the FY2025 annual figure was -$115.6 million, down 34.09% from the prior year.
- Free Cash Flow came in at -$24.1 million for Q1 2026 at Acumen Pharmaceuticals, down from -$19.1 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$6.5 million in Q2 2022 to a low of -$34.2 million in Q1 2025.
- A 5-year average of -$17.9 million and a median of -$16.5 million in 2024 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow sank 250.59% in 2022 and increased 29.83% in 2025, its largest moves.
- Acumen Pharmaceuticals' Free Cash Flow stood at -$11.2 million in 2022, then rose by 25.89% to -$8.3 million in 2023, then tumbled by 226.79% to -$27.2 million in 2024, then climbed by 29.83% to -$19.1 million in 2025, then decreased by 26.35% to -$24.1 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$24.1 million, -$19.1 million, and -$30.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Acumen Pharmaceuticals | 164.37 Mn | 35.97 Mn | - | -24.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.13 Mn |
| Mar 31, 2026 | -24.13 Mn |
| Dec 31, 2025 | -19.10 Mn |
| Dec 31, 2025 | -19.10 Mn |
| Sep 30, 2025 | -30.58 Mn |
| Sep 30, 2025 | -30.58 Mn |
| Jun 30, 2025 | -31.75 Mn |
| Jun 30, 2025 | -31.75 Mn |
| Mar 31, 2025 | -34.20 Mn |
| Mar 31, 2025 | -34.20 Mn |
| Dec 31, 2024 | -27.22 Mn |
| Dec 31, 2024 | -27.22 Mn |
| Sep 30, 2024 | -24.60 Mn |
| Sep 30, 2024 | -24.60 Mn |
| Jun 30, 2024 | -16.48 Mn |
| Jun 30, 2024 | -16.48 Mn |
| Mar 31, 2024 | -17.94 Mn |
| Mar 31, 2024 | -17.94 Mn |
| Dec 31, 2023 | -8.33 Mn |
| Dec 31, 2023 | -8.33 Mn |
| Sep 30, 2023 | -12.91 Mn |
| Sep 30, 2023 | -12.91 Mn |
| Jun 30, 2023 | -11.67 Mn |
| Jun 30, 2023 | -11.67 Mn |
| Mar 31, 2023 | -10.18 Mn |
| Mar 31, 2023 | -10.18 Mn |
| Dec 31, 2022 | -11.24 Mn |
| Dec 31, 2022 | -11.24 Mn |
| Sep 30, 2022 | -9.27 Mn |
| Sep 30, 2022 | -9.27 Mn |
| Jun 30, 2022 | -6.50 Mn |
| Jun 30, 2022 | -6.50 Mn |
| Mar 31, 2022 | -8.31 Mn |
| Mar 31, 2022 | -8.31 Mn |
| Dec 31, 2021 | -3.67 Mn |
| Dec 31, 2021 | -3.67 Mn |
| Sep 30, 2021 | -7.70 Mn |
| Sep 30, 2021 | -7.70 Mn |
| Jun 30, 2021 | -4.26 Mn |
| Jun 30, 2021 | -4.26 Mn |
| Mar 31, 2021 | -2.37 Mn |
| Mar 31, 2021 | -2.37 Mn |
| Dec 31, 2020 | -2.86 Mn |
| Dec 31, 2020 | -2.86 Mn |
| Sep 30, 2020 | -1.28 Mn |
| Sep 30, 2020 | -1.28 Mn |